The legal action centers on accusations that Immutep violated the Securities Exchange Act by concealing unfavorable data from its TACTI-004 study. While the company reported strong progress in a January 30, 2026, SEC filing, the complaint alleges management was already aware that the trial would fail to meet its primary efficacy endpoints. When these details surfaced, the resulting market reaction led to significant shareholder losses.

Brian Schall, lead counsel at the Los Angeles-based firm, is urging affected investors to come forward before the July 6, 2026, deadline. Because the class remains uncertified, shareholders currently remain absent members of the potential litigation. Those seeking to discuss their legal standing or potential recovery options may contact the firm directly at 310-301-3335.